Mechanism of protective effect of energostim during catalepsy produced by single treatment with trifluoperazine.
NAD, cytochrome c, and energostim modulated the fluorescence emission spectrum of trifluoperazine in the solution and in microsomal suspension. The data suggest that NAD and energostim modify structural and conformational characteristics of the dopamine receptor-trifluoperazine complex. These changes probably underlie the anticataleptic effect of energostim.
Chikobava
E A
EA
N. V. Karsanov Republican Research Center for Medical Biophysics and Implementation of New Biomedical Technologies, Tbilisi.
Galenko-Yaroshevskii
P A
PA
Gurskaya
E V
EV
Mamuchishvili
I G
IG
Sukoyan
G V
GV
D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000633:toxicity; D002375:Catalepsy / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D045304:Cytochromes c / Q000494:pharmacology; D008297:Male; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D009243:NAD / Q000494:pharmacology; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D014268:Trifluoperazine / Q000633:toxicity
D000975:Antioxidants; D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D009243:NAD; D014268:Trifluoperazine; D045304:Cytochromes c